Checkpoint Inhibitor-induced Liver Injury in patients with advanced melanoma and cutaneous squamous cell carcinoma: a single center experience
Year: 2025
Type: article
Abstract: Background: Immune checkpoint inhibitors (ICIs) are the first-line therapy for advanced melanoma and cutaneous squamous cell carcinoma (cSCC). Their mechanism of action lead to immune-related adverse events (irAEs), including Checkpoint Inhibitor-Induced Liver Injury (ChILI), which occurs in 5-10% of patients undergoing ICI monotherapy. ChILI is characterized by mild to severe elevation of liver function tests (LFTs), often requiring treatment discontinuation.[1][2]
Source: EJC Skin Cancer
Authors: M. Salvi, L. Quattrini, A. Liguori, F. Brunetti, S. Archilei, L. Di Nardo, A. Di Stefani, A. Grieco, K. Peris
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,340
OpenAlex ID: W4409145099